FDA and Duke-Margolis Host Workshop on Evidence Standards for Rare Diseases
The U.S. Food and Drug Administration (FDA) is partnering with the Duke-Margolis Center for Health Policy to host a public workshop aimed at addressing challenges in generating reliable evidence for rare disease treatments. The event will focus on how pharmaceutical companies can develop robust clinical data when patient populations are extremely limited, which often complicates regulatory approval processes. The workshop comes amid growing interest and investment in therapies targeting rare diseases, where traditional trial designs may not be feasible due to small patient numbers. Experts from industry, academia, and government agencies will discuss innovative methodologies for evaluating treatment efficacy with minimal data points. The FDA aims to foster a collaborative environment that could lead to more flexible regulatory frameworks. This initiative reflects the agency’s ongoing efforts to streamline drug development in niche therapeutic areas while maintaining high safety standards.
